Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease

Acta Neurochirurgica

Volumn 152, Issue 12, 2010, Pages 2063-2068

  Yamada, Kazumichi ^a   Shiraishi, Shin Ya ^a   Hamasaki, Tadashi ^b   Kuratsu, Jun Ichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

Author keywords

123I MIBG; Deep brain stimulation; Parkinson's disease; Subthalamic nucleus

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BROMOCRIPTINE; DECARBOXYLASE INHIBITOR; LEVODOPA; PERGOLIDE; ROPINIROLE; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG UPTAKE; FEMALE; HEART SCINTISCANNING; HUMAN; MALE; MEDIASTINUM; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; HEART ARRHYTHMIA; METHODOLOGY; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PATIENT SELECTION; PHYSIOLOGY; PREDICTIVE VALUE; PREOPERATIVE CARE; STANDARD; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ARRHYTHMIAS, CARDIAC; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RADIOPHARMACEUTICALS; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

EID: 78651074415     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-010-0825-0     Document Type: Article

References (30)

1. Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, Ando M (1994) Radiolabelled metaiodobenzylguanidine in assessment of autonomic dysfunction. Lancet 343:984-985
2. Braak H, Tredici KD, Rüb U, de Vos RAI, Ernst NH, Steur ENHJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
3. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, Pollak P (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59:932-934
4. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH (2009) MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism- predominant multiple system atrophy. Mov Disord 24:1650-1655
5. Erola T, Heikkinen ER, Haapaniemi T, Tuominen J, Juolasmaa A, Myllylä VV (2006) Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease. Acta Neurochir (Wien) 148:389-394
6. Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, Hirayama M, Takahashi A (1994) A radiological analysis of heart sympathetic functions with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81-84
7. Hallett M, Litvan I (1999) The task force on surgery for Parkinson's disease. Evaluation of surgery for Parkinson's disease. A report of the therapeutic and technology assessment subcommittee of the American academy of neurology. Neurology 53:1910-1921
8. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body disease. Neurology 52:1269-1271
9. Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2008) Prognostic value of serial cardiac 123IMIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 49:907-914
10. Katayama Y, Kasai M, Oshima H, Fukaya C, Yamamato T, Ogawa K, Mizutani T (2001) Subthalamic nucleus stimulation for Parkinson disease: Benefits observed in levodopa-intolerant patients. J Neurosurg 95:213-221
11. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. Mov Disord 21(Suppl 14):S290-S304
12. Krack P, Batir A, van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin P, Benazzouz A, LeBas JF, Benabid A-L, Pollak P (2003) A five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Eng J Med 349:1925-1934
13. Langston JW (2006) The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59:591-596
14. Lyons KE, Davis JT, Pahwa R (2007) Subthalamic stimulation in Parkinson's disease patients intolerant to levodopa. Stereotact Funct Neurosurg 85:169-174
15. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P (1992) Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471-477
16. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53:85-90
17. Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, Nakazato M, Yamashita S, Arita H, Nishii R, Kawai K (2008) Usefulness of rCBF analysis in diagnosing Parkinson's disease: Supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 22:557-564
18. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76:249-251
19. Orimo S, Ozawa E, Oka T, Nakade S, Tsuchiya K, Yoshimoto M, Wakabayashi K, Takahashi H (2001) Differentional histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57:1140-1141
20. Østergaard K, Sunde N, Dupont E (2002) Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 17:693-700
21. Post KK, Singer C, Papapetropoulos S (2008) Cardiac denervation and dysautonomia in Parkinson's disease: A review of screening techniques. Parkinsonism Relat Disord 14:524-531
22. Romito LM, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A (2002) Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology 58:1546-1550
23. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K (2000) Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566-573
24. Taki J, Yoshita M, Yamada M, Tonami N (2004) Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 18:453-461
25. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL (2008) Prognostic value of myocardinal 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systemic review. Eur Heart J 29:1147-1159
26. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up. Neurology 58:396-401
27. Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Agid Y et al (2002) Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 125:575-583
28. Yamada K, Goto S, Hamasaki T, Kuratsu J-I (2008) Effect of bilateral subthalamic nucleus stimulation on levodopaunresponsive axial symptoms in Parkinson's disease. Acta Neurochir (Wien) 150:15-22
29. Yamada K, Goto S, Kuratsu J, Matsuzaki K, Nagahiro S, Shimazu H, Kaji R (2007) General anesthesia for stereotactic implantation of stimulating electrodes within the subthalamic nucleus. Parkinsonism Relat Disord 13:101-107
30. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M,Matsumoto Y, Nakajima K, Yamada M (2006) 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850-1854